Open an account

Artiva Biotherapeutics

ARTV · NASDAQ

$6.56+$0.67 (+11.38%)TodayMarket closed ·
Prev close $5.89

About ARTV

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. The company is headquartered in San Diego, California and currently employs 104 full-time employees. The company went IPO on 2024-07-19. The firm is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.

Employees
104
Headquarters
San Diego, California
Listed
Jul 19, 2024
Sector
Health Care
Industry
Biotechnology
Website
artivabio.com

ARTV key statistics

Market cap
320.72M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
475.53K
Volume
449.94K
Open price
$5.89
High today
$6.65
Low today
$5.86
52 Week high
$14.53
52 Week low
$2.96

Artiva Biotherapeutics (ARTV) at a glance

Artiva Biotherapeutics (ARTV) last traded at $6.56, with a market cap of 320.72M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $5.86 and $6.65. The current price is 11.9% above the day's low and 1.4% below its high.

Volume so far is 449.94K shares, in line with the average of 475.53K shares a day.

Over the past year Artiva Biotherapeutics has ranged from $2.96 to $14.53, and now sits 31% of the way up that range.

Artiva Biotherapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.63 per share against an estimate of -$0.6375.

The average analyst price target is $36.52, 456.6% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $36.52
Low
$23.23
Now
$6.56
High
$43.05

ARTV earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 4.3% on average.

  1. Q3 FY24: reported -$0.925 per share against an estimate of -$0.9316
  2. Q4 FY24: reported -$0.66 per share against an estimate of -$0.7701
  3. Q1 FY25: reported -$0.83 per share against an estimate of -$0.7247
  4. Q2 FY25: reported -$0.87 per share against an estimate of -$0.8228
  5. Q3 FY25: reported -$0.88 per share against an estimate of -$0.8874
  6. Q4 FY25: reported -$0.85 per share against an estimate of -$0.8429
  7. Q1 FY26: reported -$0.95 per share against an estimate of -$0.8896
  8. Q2 FY26: reported -$0.63 per share against an estimate of -$0.6375

ARTV news

  • Press releaseGlobe Newswire

    Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease

  • Press releasePRNewswire

    The $13 Million Company Teaching the Immune System to Hunt Cancer

  • Press releasePRNewswire

    Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

  • Vandana Singh

    Artiva Biotherapeutics Stock Slides Despite Positive Trial Data

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Market-Moving News for May 8th

  • Avi Kapoor

    Sonoco Products Posts Downbeat Q1 Results, Joins Target Hospitality, Calix And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

  • Press releasePRNewswire

    Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines

Similar companies

Companies in the same industry as Artiva Biotherapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.